122 related articles for article (PubMed ID: 33952461)
1. Comparative Evaluation of Cellular Uptake of Free and Liposomal Doxorubicin Following Short Term Exposure.
Zaleskis G; Garberyte S; Pavliukeviciene B; Krasko JA; Skapas M; Talaikis M; Darinskas A; Zibutyte L; Pasukoniene V
Anticancer Res; 2021 May; 41(5):2363-2370. PubMed ID: 33952461
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin.
Ren S; Dai Y; Li C; Qiu Z; Wang X; Tian F; Zhou S; Liu Q; Xing H; Lu Y; Chen X; Li N
Eur J Pharm Sci; 2016 Sep; 92():137-45. PubMed ID: 27388491
[TBL] [Abstract][Full Text] [Related]
4. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma.
Kullenberg F; Degerstedt O; Calitz C; Pavlović N; Balgoma D; Gråsjö J; Sjögren E; Hedeland M; Heindryckx F; Lennernäs H
Cells; 2021 Jul; 10(7):. PubMed ID: 34359887
[TBL] [Abstract][Full Text] [Related]
6. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
[TBL] [Abstract][Full Text] [Related]
8. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of liposomal doxorubicin hydrochloride with palm oil.
Sabeti B; Noordin MI; Mohd S; Hashim R; Dahlan A; Javar HA
Biomed Res Int; 2014; 2014():765426. PubMed ID: 24795894
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
11. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
12. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
[TBL] [Abstract][Full Text] [Related]
13. Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling.
Soininen SK; Vellonen KS; Heikkinen AT; Auriola S; Ranta VP; Urtti A; Ruponen M
Mol Pharm; 2016 Apr; 13(4):1358-65. PubMed ID: 26950248
[TBL] [Abstract][Full Text] [Related]
14. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.
Riviere K; Huang Z; Jerger K; Macaraeg N; Szoka FC
J Drug Target; 2011 Jan; 19(1):14-24. PubMed ID: 20353291
[TBL] [Abstract][Full Text] [Related]
16. Human placental cell and tissue uptake of doxorubicin and its liposomal formulations.
Soininen SK; Repo JK; Karttunen V; Auriola S; Vähäkangas KH; Ruponen M
Toxicol Lett; 2015 Dec; 239(2):108-14. PubMed ID: 26383631
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines.
Chen L; Alrbyawi H; Poudel I; Arnold RD; Babu RJ
AAPS PharmSciTech; 2019 Feb; 20(3):99. PubMed ID: 30719596
[TBL] [Abstract][Full Text] [Related]
18. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
20. Self-crosslinkable and intracellularly decrosslinkable biodegradable micellar nanoparticles: A robust, simple and multifunctional nanoplatform for high-efficiency targeted cancer chemotherapy.
Zou Y; Fang Y; Meng H; Meng F; Deng C; Zhang J; Zhong Z
J Control Release; 2016 Dec; 244(Pt B):326-335. PubMed ID: 27245309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
